Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025
Seres Therapeutics (MCRB) has scheduled a conference call and live audio webcast for March 13, 2025, at 8:30 a.m. ET to discuss their fourth quarter and full year 2024 financial results along with business updates. Interested participants can access the conference call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) using conference ID 6331602. The webcast will be available in the Investors and News section of the Seres website, with a replay accessible approximately two hours after the event and archived for about 21 days.
Seres Therapeutics (MCRB) ha programmato una conferenza telefonica e una trasmissione audio in diretta per il 13 marzo 2025, alle 8:30 a.m. ET per discutere i risultati finanziari del quarto trimestre e dell'intero anno 2024, insieme agli aggiornamenti aziendali. I partecipanti interessati possono accedere alla conferenza telefonica componendo 800-715-9871 (nazionale) o 646-307-1963 (internazionale) utilizzando l'ID conferenza 6331602. La trasmissione sarà disponibile nella sezione Investitori e Notizie del sito web di Seres, con una registrazione accessibile circa due ore dopo l'evento e archiviata per circa 21 giorni.
Seres Therapeutics (MCRB) ha programado una llamada de conferencia y una transmisión de audio en vivo para el 13 de marzo de 2025, a las 8:30 a.m. ET para discutir sus resultados financieros del cuarto trimestre y del año completo 2024, junto con actualizaciones comerciales. Los participantes interesados pueden acceder a la llamada de conferencia marcando 800-715-9871 (nacional) o 646-307-1963 (internacional) utilizando el ID de conferencia 6331602. La transmisión estará disponible en la sección de Inversores y Noticias del sitio web de Seres, con una repetición accesible aproximadamente dos horas después del evento y archivada durante unos 21 días.
Seres Therapeutics (MCRB)는 2025년 3월 13일 오전 8시 30분 ET에 2024년 4분기 및 연간 재무 결과와 비즈니스 업데이트를 논의하기 위한 컨퍼런스 콜 및 라이브 오디오 웹캐스트를 예정하고 있습니다. 관심 있는 참가자는 800-715-9871 (국내) 또는 646-307-1963 (국제)로 전화하여 컨퍼런스 ID 6331602를 사용하여 컨퍼런스 콜에 접속할 수 있습니다. 웹캐스트는 Seres 웹사이트의 투자자 및 뉴스 섹션에서 이용 가능하며, 이벤트 후 약 2시간 후에 재생이 가능하고 약 21일 동안 아카이브됩니다.
Seres Therapeutics (MCRB) a prévu une conférence téléphonique et un webinaire audio en direct pour le 13 mars 2025, à 8h30 ET, afin de discuter des résultats financiers du quatrième trimestre et de l'année complète 2024, ainsi que des mises à jour commerciales. Les participants intéressés peuvent accéder à la conférence téléphonique en composant le 800-715-9871 (national) ou le 646-307-1963 (international) en utilisant l'ID de conférence 6331602. Le webinaire sera disponible dans la section Investisseurs et Actualités du site web de Seres, avec un replay accessible environ deux heures après l'événement et archivé pendant environ 21 jours.
Seres Therapeutics (MCRB) hat eine Telefonkonferenz und einen Live-Audio-Webcast für den 13. März 2025, um 8:30 Uhr ET angesetzt, um die finanziellen Ergebnisse des vierten Quartals und des gesamten Jahres 2024 sowie Geschäftsupdates zu besprechen. Interessierte Teilnehmer können die Telefonkonferenz unter 800-715-9871 (national) oder 646-307-1963 (international) mit der Konferenz-ID 6331602 erreichen. Der Webcast wird im Bereich Investoren und Nachrichten auf der Seres-Website verfügbar sein, mit einer Wiederholung, die etwa zwei Stunden nach der Veranstaltung zugänglich ist und etwa 21 Tage lang archiviert wird.
- None.
- None.
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on March 13, 2025 at 8:30 a.m. ET to discuss fourth quarter and full year 2024 financial results and provide business updates.
To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 6331602. To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit www.serestherapeutics.com.
Investor and Media Contact:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
When will Seres Therapeutics (MCRB) report Q4 and full year 2024 earnings?
How can investors join Seres Therapeutics (MCRB) Q4 2024 earnings call?
How long will MCRB's Q4 2024 earnings webcast replay be available?
Where can I find MCRB's Q4 2024 earnings webcast?
